Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edesa Biotech (EDSA) Share-based Compensation (2016 - 2022)

Edesa Biotech's Share-based Compensation history spans 10 years, with the latest figure at $455964.0 for Q3 2022.

  • For Q3 2022, Share-based Compensation fell 49.6% year-over-year to $455964.0; the TTM value through Sep 2022 reached $2.3 million, down 29.26%, while the annual FY2025 figure was $700000.0, 40.0% up from the prior year.
  • Share-based Compensation for Q3 2022 was $455964.0 at Edesa Biotech, down from $565384.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.1 million in Q2 2021 and bottomed at -$316599.0 in Q3 2018.
  • The 5-year median for Share-based Compensation is $380000.0 (2020), against an average of $338059.7.
  • The largest annual shift saw Share-based Compensation tumbled 81.7% in 2019 before it skyrocketed 8138.28% in 2020.
  • A 5-year view of Share-based Compensation shows it stood at $11434.0 in 2018, then dropped by 23.26% to $8775.0 in 2019, then surged by 8138.28% to $722909.0 in 2020, then dropped by 15.72% to $609278.0 in 2021, then decreased by 25.16% to $455964.0 in 2022.
  • Per Business Quant, the three most recent readings for EDSA's Share-based Compensation are $455964.0 (Q3 2022), $565384.0 (Q2 2022), and $630008.0 (Q1 2022).